| 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股 东的净利润 | -86,500.00 万元至-60,700.00 万元 | -92,516.99 万元 | | 扣除非经常性损益 后的净利润 | -93,800.00 万元至-65,800.00 万元 | -82,265.31 万元 | | 基本每股收益 | -0.62 元/股至-0.43 元/股 | -0.66 元/股 | 达安基因2025年前三季度营收5.04亿元，归母净利润-1.42亿元。综合年报预告来看，第四季度下滑明显。 公司2025年度业绩变动的主要原因为： （一）报告期内，受市场需求、集采等医保控费政策深化执行和自产试剂产品增值税税率调整为13%的影响，公司营业收入减少；同时， 在报告期内，公司积极采取各项开源节流举措，提升精细化经营能力，但因公司运营成本、人力成本等固定成本开支较大，收入规模下降 幅度短期内难以匹配成本下降幅度，对公司综合毛利造成负面影响，导致本年度出现经营亏损； 1月30日，达安基因公告称，2025年预计归属于上市公司股东的净利润为-8.65亿元至-6.07亿元，上年同期为 ...

南财智讯1月30日电，达安基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-60,700.00万元至-86,500.00万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-93,800.00万元至-65,800.00万元。公司2025年度业绩变动的主要原因为：（一）报告期内，受市场需 求、集采等医保控费政策深化执行和自产试剂产品增值税税率调整为13%的影响，公司营业收入减少； 同时，在报告期内，公司积极采取各项开源节流举措，提升精细化经营能力，但因公司运营成本、人力 成本等固定成本开支较大，收入规模下降幅度短期内难以匹配成本下降幅度，对公司综合毛利造成负面 影响，导致本年度出现经营亏损；（二）报告期内，公司联营企业的业绩较上年同期好转，公司对联营 企业确认的投资收益较上年同期增加，归属于上市公司股东的净利润较上年同期增加；（三）报告期 内，公司加强历史应收账款的催收回款力度，取得一定成果，计提的应收账款信用减值损失金额较上年 同期减少；报告期内，公司对各类资产进行了全面清查，基于谨慎性原则，对存在减值迹象的相关资产 （包括存货、固定资产、无形资产、在建工程、其他长期 ...

报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政策陆续执行导致价格下降和自产试剂 产品增值税税率调整为13%导致收入下降;财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时 公司在积极应对市场竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场竞 争力，提升公司经营能力。 之江生物(688317.SH)发布2025年年度业绩预告，预计实现归属于母公司所有者的净利润-3,200万元 到-4,700万元。与上年同期相比，净利润将减少亏损8,046.21万元到9,546.21万元，同比减亏幅度63.13% 到74.89%。 ...

Core Viewpoint - Zhijiang Biotech (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in losses of 80.46 million to 95.46 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in losses of 70.27 million to 89.27 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additional factors contributing to the losses include a decrease in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

Core Viewpoint - Zhijiang Biotechnology (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in loss of 80.4621 million to 95.4621 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in loss of 70.2713 million to 89.2713 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additionally, a decrease in financial income and foreign exchange gains has contributed to the overall performance decline [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

智通财经APP讯，之江生物(688317.SH)发布2025年年度业绩预告，预计实现归属于母公司所有者的净 利润-3,200万元到-4,700万元。与上年同期相比，净利润将减少亏损8,046.21万元到9,546.21万元，同比 减亏幅度63.13%到74.89%。 报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政策陆续执行导致价格下降和自产试剂 产品增值税税率调整为13%导致收入下降;财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时 公司在积极应对市场竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场竞 争力，提升公司经营能力。 ...